Glaxo Wellferon Launch For Hepatitis C Awaits Manufacturing Change
Executive Summary
The launch of Glaxo Wellcome's hepatitis C treatment Wellferon (interferon alfa-n1, lymphoblastoid) will await the implementation of a manufacturing change, Glaxo said following Wellferon's March 25 approval.
You may also be interested in...
Wyeth-Ayerst To Produce Enbrel At Former Glaxo Wellferon Site
Wyeth-Ayerst plans to manufacture the rheumatoid arthritis therapy Enbrel at a West Greenwich, R.I. biopharmaceutical facility purchased from Glaxo.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011